logo-loader

Rexahn Pharmaceuticals Presents Serdaxin Phase IIa Clinical Data at the American College of Neuropsychopharmacologists

Last updated: 01:17 09 Dec 2010 GMT, First published: 02:17 09 Dec 2010 GMT

no_picture_pai

Rexahn Pharmaceuticals (NYSE AMEX:RNN), a clinical stage pharmaceutical company based in Rockville, Maryland, announced today that clinical data on the antidepressant activity of its Serdaxin drug were presented yesterday at the American College of Neuropsychopharmacologists Annual Meeting, held in Miami Beach, Florida.

The data, which comes from Serdaxin’s Phase IIa study, was presented by Joshua Rosenthal, one of the co-authors of the study.

The study’s results, which were first announced back in April by Rexahn, showed that patients with severe major depressive disorder taking 5 mg of Serdaxin had statistically significant improvement in Montgomery-Asberg Depression Rating Scale scores after 8 weeks of treatment, compared to a placebo. 

"Serdaxin represents a new mechanism and approach to anti-depression therapy by enhancing both the serotonin and dopamine activity of neural transmitters. We believe this approach has the potential to help a broader spectrum of patients than the currently marketed therapeutics," said Rick Soni, the Chief Operating Officer of Rexahn.

According to the company, Serdaxin has also shown neuroprotective potential in animals treated with neurotoxins, and may have important applications in the treatment of human neurodegenerative disorders such as Parkinson's disease and Alzheimer disease. Animal model studies also suggest that Serdaxin reduces aggressive behavior and relieves anxiety, Rexahn said.

The company said it plans to initiate a larger phase IIb clinical trial, involving about 300 patients, in the second half of 2010.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

29 minutes ago